A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer

Exclusion Criteria15

• Known to have microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR).
• Imaging shows obvious tumor necrosis or cavitation, and the investigator judges that participation in the study may increase the risk of bleeding.
• Subjects with brain metastases.
• Toxicities from prior anti-tumor therapy have not recovered to ≤ grade 1 according to NCI-CTCAE v6.0.
• Known hypersensitivity or delayed-type allergy to any component of the study drug or similar drugs.
• Subjects with refractory nausea and vomiting, chronic gastrointestinal diseases, or other diseases that may interfere the adequate absorption, distribution, metabolism, or excretion of oral drugs.
• Subjects with acute, chronic, or symptomatic infections.
• Subjects with diagnosed or suspected interstitial lung disease (ILD), drug-related pneumonia, radiation pneumonitis, severe impairment of lung function, or other lung diseases.
• Subjects with active inflammatory bowel disease, a history of gastrointestinal perforation and/or fistula, or clinical symptoms of gastrointestinal obstruction.
• Subjects with severe arterial/venous thromboembolic events within 6 months before randomization.
• Active gastrointestinal bleeding, hemoptysis, peptic ulcer, or hemorrhagic events requiring intervention within 28 days before randomization; or presence of severe esophagogastric varices or epistaxis.
• Presence of symptomatic or intervention-requiring third-space effusions.
• Subjects with active or previously diagnosed autoimmune diseases that may recur.
• History of other invasive malignant tumors within 5 years before randomization, or presence of any residual evidence of previously diagnosed malignant tumors.
• Subjects who are pregnant, lactating, or planning to become pregnant.